CAR T-cell therapy for worsening multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple sclerosis that is getting worse despite treatment.
- You have had a relapse, worsening disability, or new MRI lesions in the past year.
- You have had certain advanced MS treatments (like ocrelizumab, natalizumab) for at least 6 months.
- You are fully vaccinated against hepatitis B and have antibodies for VZV (chickenpox) and EBV.
- You have adequate blood cell counts and organ function.
- You do not have other major health conditions like active infections, cancer, or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental treatment called C-CAR168, which uses your own immune cells that have been modified to target and potentially slow down the progression of multiple sclerosis. It is for younger adults with progressive MS who have not responded well to standard treatments.
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This trial tests a new cell therapy called C-CAR168, which uses a patient's own immune cells to target and potentially reset the immune system to treat conditions like multiple sclerosis, lupus, and myasthenia gravis. It's for people whose disease has not improved with standard treatments.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.